Shastri Toral, Randhawa Navkiran, Aly Ragia, Ghouse Masood
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA.
Franciscan Health, Olympia Fields, IL, USA.
J Blood Med. 2022 Feb 18;13:69-74. doi: 10.2147/JBM.S350290. eCollection 2022.
As of September 2021, SARS-CoV-2 booster shots became widely available in the US to ensure continued protection against the virus. A temporal relationship has been previously reported between the first or second dose of the COVID-19 vaccine and the development of thrombocytopenia. However, adverse events related to the third COVID-19 vaccine are still being reported and studied. We report a 74-year-old male who developed bone marrow suppression and pancytopenia recorded seven days after receiving the Pfizer SARS-CoV-2 vaccine. During his hospital stay, the patient's hemoglobin, white blood cell, and platelet levels continued to trend downwards. However, all three levels showed improvement one week after discharge without robust intervention. Global vaccination is of utmost importance, as is understanding and documenting post-vaccination reactions including bone marrow suppression. Prompt evaluation and patient education are imperative to improve patient outcomes and combat hesitancy against vaccine administration.
截至2021年9月,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)加强针在美国广泛可用,以确保持续预防该病毒。先前已有报告称,新型冠状病毒肺炎(COVID-19)疫苗的第一剂或第二剂与血小板减少症的发生存在时间关系。然而,与第三剂COVID-19疫苗相关的不良事件仍在报告和研究中。我们报告一名74岁男性,在接种辉瑞SARS-CoV-2疫苗七天后出现骨髓抑制和全血细胞减少。在他住院期间,患者的血红蛋白、白细胞和血小板水平持续下降。然而,出院一周后,在没有强力干预的情况下,所有这三个水平均有所改善。全球疫苗接种至关重要,了解和记录包括骨髓抑制在内的接种后反应同样重要。及时评估和对患者进行教育对于改善患者预后和消除对疫苗接种的犹豫情绪至关重要。